Re:Search Institution Members

89 Results for Members


Former member - Now part of Pfizer Inc.

iThemba Pharmaceuticals ( is a company set up in South Africa with the specific aim of...

Kineta is a privately held emerging biotech company that was founded in 2008.

Usmanu Danfodiyo University, Sokoto (UDUS) was founded in 1975 as one of the initial twelve federal government...

The Institut Pasteur de Montevideo (IP Montevideo) is one of the most recent affiliates of the Institut...

128 Results for Collaborations


A McGill University researcher provided a UBC researcher with frozen cell extracts of Cryptosporidium infected cells. The UBC researcher used these extracts to identify potential antigens for use in a vaccine.

A McGill University researcher will provide a UBC researcher with frozen cell extracts of T. cruzi infected cells. The UBC researcher will use these extracts to identify potential antigens for use in a vaccine.

PATH and a researcher from McMaster University co-developed a microfluidic diagnostic to detect bacteria in banked milk.

Merck KGaA, Darmstadt, Germany will provide a University of California, San Diego (UCSD) investigator with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. The UCSD investigator will screen these inhibitors for activity against the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis.

Merck KGaA, Darmstadt, Germany will provide a University of Buea researcher with a subset of highly potent Hsp90 inhibitors to screen against Onchocerca worms, and identify compounds that selectively kill both microfilariae and adult O. volvulus, without adverse effects to Loa loa microfilariae.

MSD provided an Emory University researcher studying tuberculosis with membrane-bound protein purification expertise.

127 Results for Assets


A new platform based on live or chemically inactivated killed rabies virus RABV virions containing EBOV glycoprotein GP in their envelope. In preclinical trials, immunization with such recombinant RABV virions provided excellent protection in mice against lethal challenge with the mouse adapted EBOV and RABV. More specifically, the inventors have developed a trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. The efficiency of these vaccines against challenge with EBOV, MARV and RABV will be studied in multiple preclinical studies. Live attenuated vaccines are being developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines are being developed for use in humans.
Leishmania parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites. Sand fly saliva is known to enhance Leishmania infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of Leishmania major, Phlebotomus papatasi, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent Leshmaniasis. The inventors have shown that one of these salivary proteins was able to protect vaccinated mice challenged with parasites plus salivary gland homogenates (SGH). A DNA vaccine containing the cDNA for the same protein provided this same protection. Protection lasted at least 3 months after immunization. The vaccine produced both intense humoral and delayed-type hypersensitivity (DTH) reactions. B cell-deficient mice immunized with the plasmid vaccine successfully controlled Leishmania infection when injected with Leishmania plus SGH.
Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia Trachomatis. More information is available here: . Chlamydia trachomatis is the leading sexually transmitted infectious agent in the United States, causing about 10 million new cases per year. It is a major cause of involuntary infertility in women. This invention claims the DNA sequences, and their encoded amino acid sequences, of the four variable domains from the major outer membrane protein MOMP of Chlamydia trachomatis, from the serovars Ba, D, E, F, G, H, I, J, K and L3. Serovars D, E, F, G, H, I, J, and K are the most common serovars associated with Chlamydia trachomatis caused sexually transmitted diseases. The claimed variable domains of MOMP contain the major antigen targets of protective immunity including neutralizing antibodies capable of preventing chlamydial infection. Thus, these sequences are useful for the development of recombinant protein, peptide, and DNA based vaccines against C. trachomatis caused sexually transmitted diseases. The variable domains also represent the primary serotyping antigenic determinants of C. trachomatis organisms making these variable domain sequences potential useful targets for the development of DNA or antibody based diagnostic assays for C. trachomatis. The invention is described further in Ying et al., Infection and Immunity 57, 1040-1049, 1989. Zhang et al., J. Infect. Dis. 176, 1035 - 1040, 1997 describes DNA vaccines utilizing MOMP DNA.
This invention is a continuation of U.S. Patent Application 07/912,294, which described Pfs28 a 28 kd protein found in Plasmodium gallinaceum. The new application describes a unique 28 kd protein expressed on the surface of ookinetes of Plasmodium falciparum (Pfs28). This protein is useful as a malaria transmission blocking vaccine. This technology contains claims to: the Pfs28 protein; Pfs28's amino acid and nucleic acid sequences; pharmaceutical compositions containing the polypeptide and nucleic acid sequences; and methods of preventing transmission of malaria using these pharmaceutical compositions. {RefNo is 1184 }
This invention describes the design and synthesis of a multi-peptide conjugate (MPC) system containing antigens from the human malaria parasite (Plasmodium falciparium) and the Tat protein of HIV type-1 (HIV-1-Tat) for use as a subunit vaccine. The current multiple peptide conjugates (MPCs) have distinct advantages over prior MAPs because only two adjacent peptide branches are elongated on the solid phase at either the alpha or epsilon amino groups thereby allowing maximum spacing between the resin bound peptide chains. These peptides are then reacted with high performance liquid chromatography purified haloacetyl peptides to generate multiple peptide conjugates with molecular masses of 10 to 13 kDa.
The pMOD plasmid will have utility in construction of transposons for use in genetic manipulation of Mycobacteria including M.tuberculosis. Previous methods for transposon mutagenesis of Mycobacteria were cumbersome and inefficient. The pMOD plasmid is an integral part of a transposition system that is technically easy and quite efficient. This plasmid will also likely be useful for genetic manipulation of other bacteria and fungi. It would therefore be a very useful tool for molecular biologic and genetic research involving these organisms.